Repairing TMZ-caused DNA damage in glioblastoma cells
Official title: Repair of temozolomide-induced DNA damage in transcribed genes
Funded at State University New York Stony Brook · NIH-11431105 · Data updated 2026-11-12
A scientist team will study how temozolomide damages DNA in brain cancer cells and how the cells repair that damage, which may reveal new ways to overcome drug resistance.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $532,553 |
| NIH project number | 1R01CA315976-01 |
| Project ID | NIH-11431105 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with glioblastoma or those whose tumors have TMZ exposure data available could be relevant for future translational work.
✕Less likely to help
Individuals without glioblastoma or without a tumor context related to TMZ are unlikely to benefit from these findings.
What this research studies
This project focuses on glioblastoma, a deadly brain cancer, and investigates how the cancer cells fix the DNA damage caused by the chemotherapy drug temozolomide. Researchers will use glioblastoma cells and large patient datasets to map repair processes that occur during transcription and how these processes influence treatment resistance. The study builds on existing data to understand how specific repair pathways, like TC-NER, respond to alkylation damage and shape mutation patterns. The goal is to identify vulnerabilities in how GBM cells repair damage from TMZ that could be targeted in future therapies.
Why it matters
Potential benefit: If successful, the findings could lead to strategies to prevent TMZ resistance and improve treatment responses for people with glioblastoma.
How similar studies have gone: Previous work has linked transcription-coupled repair to TMZ response, but the exact role in GBM and TC-NER’s contribution are still being clarified, making this a promising but exploratory study.
Where this research is happening
-
State University New York Stony Brook
Stony Brook, United States Active
Researchers
- Principal investigator: Mao, Peng — State University New York Stony Brook
- Study coordinator: Mao, Peng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.